Zika Vaccines Market - Size & Upcoming Industry Trends 2024-2032

Zika Vaccines Market Synopsis:

Zika Vaccines Market Size Was Valued at USD 19.1 Billion in 2023, and is Projected to Reach USD 30.2 Billion by 2032, Growing at a CAGR of 5.2% From 2024-2032.

The Zika Vaccines Market encompasses all the global industries that are involved in research, development, manufacturing and marketing of vaccines against Zika virus. Zika virus, spread mainly by the Aides mosquito was recognised as a major international health concern because of its link to the neural tube abnormalities like microcephaly in newborns and other neurological complications in adults. The market involves different forms of vaccine technology which includes inactivated vaccines, live attenuated vaccines, DNA vaccines each developed to afford immunities against the virus. As the frequency of Zika outbreaks rises, particularly in tropical and subtropical parts of the world, and as more people become informed about the consequences of the disease, there has been a growing require for vaccines, which is likely to increase fund flow in research activities. New programs rolled out by governments, global health care bodies and funding from pharmaceutical companies and manufacturers among others have even more propelled the market to a higher level.

The Zika Vaccines Market has experienced a fair amount of interest within the last decade with the increase of the virus’s emergence in 2015-2016 with terrible consequences for human health and the development of newborns. This market is further driven by a rich development pipeline in the vaccine production space supported by pharma companies, academics and global health organizations. Different countries throughout the world, particularly those in Central and Latin America, the South Pacific, and Africa have geared towards mass immunization in order to reduce the effects of future epidemics. In addition, collaborations between different global health stakeholders, like WHO and the Gates Foundation, have availed funds and expertise essential for vaccine production and delivery.

Another factor which is fueling this market is the constant advancements being made in vaccines technology. Discovered and Developed mRNA and DNA vaccines are all new ways of containing viral diseases such as the zika virus. Quite unambiguously, these technologies provide the benefits of miniaturization and high effectiveness, which could advocate for their use in large scale vaccination. However, factors like high costs involved in manufacturing, leadership to production and quality control standards, as well as operational difficulties due to geographical inaccessibility of large poor consumer base continues to be) major practically insurmountable barriers for the status quo in the global market share.

Zika Vaccines Market Trend Analysis:

Rising Demand for DNA-Based Vaccines

• Another trend in the Zika Vaccines Market is the highest growth pertaining to DNA-based vaccines. DNA vaccines have attracted interest due to their apparent capacity to provoke robust immune reactions, as well as generally possessing a shorter time to development than conventional vaccines. It has been encouraged by past outcomes of similarly designed platforms in containing other viral ailments, like coronavirus. Major drug stakeholders are deploying this technology in new Zika vaccine production, which, if successful, will redefine the market. These platforms are becoming popular since they are stable, cheap, and doe the job well especially for the Zika virus which has varying mutation rates and genotypes.

Expansion in Emerging Markets

• Latin America and Southeast Asia have attractive opportunities for the Zika Vaccines Market. These areas have often times been affected by Zika epidemics therefore generating a market for preventive measures. Governments within these regions are putting their money in mass immunization as a way of shielding special groups including pregnant mothers. More so, advancement in health care facilities coupled with enhanced sensitization on the zika virus in these expanding economies of the global continent are ideal for the launch of the vaccines. Another driver is partnerships between provincial governments and global health organisations that are enabling affordable vaccination, thus opening up major market opportunities.

Zika Vaccines Market Segment Analysis:

Zika Vaccines Market Segmented on the basis of type, and application.

By Type, Inactivated Vaccine segment is expected to dominate the market during the forecast period

• Thus, the inactivated vaccine segment holds the largest share in the Zika Vaccines Market throughout the forecast period due to its safety and effectiveness. While live attenuated vaccines, the virus is weakened but not killed, therefore this type of vaccine has no risk of reverting to virulent type. It also enhances their suitability for consumption especially in foetal and immune-compromised compartments such as pregnancy and immunological status respectively. On the same note, the production procedures for inactivated vaccines are well set hence quick to scale up as well as widespread.
• This segment is also on the rise due to the success of clinical trial from some of the candidates which has posed to be very effective with regards to immunogenicity and seems to have little side effects. Stakeholders are focusing on inactivated vaccines to address the small quantity and high quality of safe solutions for early treatment. Governments and health organizations are also promoting the use of these vaccines making them also contribute to market share.

By Application, Clinics segment expected to held the largest share

• Clinics are expected to dominate the Zika Vaccines Market through the forecast period because clinics are the main places where immunizations are administered, in cities and the countryside alike. Clinics are most important for vaccination campaigns since they provide proper access and rather cheap service to population. This increases their efficacy in terms of care since they can closely observe the patient’s response to available vaccines making them thr favorite distribution channel.
• Moreover, clinics participate in immunization government campaigns, which helps them deliver the service to remote areas. The increasing number of clinics specifically targeting maternal and child health issues in areas of the world with high incidences of malaria should lend support to the segment. Such strategies also include partnerships between the healthcare givers and vaccine developers in also increasing the likelihood of having Zika vaccines in clinics.

Zika Vaccines Market Regional Insights:

Latin America is Expected to Dominate the Market Over the Forecast period

• South American countries led the Zika Vaccines Market in 2023 and held a 35% market share in the global market. Higher leadership in the region can be explained with reference to heavier burden of Zika cases in the area stimulating strong funding in the vaccine and research projects. These include Brazil, Colombia and Mexico, among others; while governments use different approaches to make available vaccines to combat the virus. The region has also boasted of a strong healthcare system and preventive health polices that has also enhanced its lead. Further, international partnerships, and grant support from global health institutions, have boosted the vaccine administration in the Latin American region that has effectively positioned itself as the leading regional market.

Active Key Players in the Zika Vaccines Market:

• Bharat Biotech (India)
• Emergent BioSolutions (USA)
• GeneOne Life Science (South Korea)
• GlaxoSmithKline (UK)
• Inovio Pharmaceuticals (USA)
• Johnson & Johnson (USA)
• Moderna, Inc. (USA)
• NewLink Genetics (USA)
• Novavax, Inc. (USA)
• Pfizer Inc. (USA)
• Sanofi S.A. (France)
• Serum Institute of India (India)
• Takeda Pharmaceutical (Japan)
• Themis Bioscience (Austria)
• Vaxart, Inc. (USA)
• Other Active Players